Immune globulin - LFB Biotechnologies

Drug Profile

Immune globulin - LFB Biotechnologies

Alternative Names: Clairyg; I10E; Immunoglobulin liquid intravenous - LFB Biotechnologies; Iqymune

Latest Information Update: 13 Sep 2016

Price : $50

At a glance

  • Originator LFB Biotechnologies
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Autoimmune disorders; Immunodeficiency disorders
  • Phase III Chronic inflammatory demyelinating polyradiculoneuropathy; Motor neuron disease

Most Recent Events

  • 01 Jul 2016 LFB Biotechnologies completes a phase III trial in Motor Neuron Disease in France, Italy, Spain and United Kingdom (NCT01951924)
  • 15 Mar 2016 Biomarkers information updated
  • 30 Mar 2015 LFB Biotechnologies initiates the phase III PRISM I trial in Chronic inflammatory demyelinating polyradiculoneuropathy in United Kingdom (UKCRN17067)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top